AOA-OMED Research Posters 2024-OMED24-POSTERS

Video Transcription

Video Summary

In this research presentation, Macy Fulmer, a medical student, discusses a meta-analysis comparing adverse events from nivolumab alone versus its combination with ipilimumab in treating melanoma. Nivolumab and ipilimumab, both immune checkpoint inhibitors, boost the immune response against tumors. The study analyzed published trials and found that nivolumab monotherapy results in significantly fewer adverse events affecting the endocrine, gastrointestinal, and integumentary systems compared to the combination therapy. The findings suggest that combining ipilimumab with nivolumab raises the risk of adverse events, advocating for careful consideration in treatment planning.

Keywords

nivolumab

ipilimumab

melanoma

adverse events

immune checkpoint inhibitors